中国急性缺血性卒中静脉溶栓现状

Current status of intravenous thrombolysis for acute ischemic stroke in China

从1995年起,静脉溶栓治疗就成为世界范围内广泛应用的治疗急性缺血性卒中最有效的方法之一。然而,在中国仅有4%~5%的缺血性卒中患者有机会接受到静脉阿替普酶的治疗。文章简介中国静脉溶栓治疗之现状,探讨目前存在的问题、相关因素、变化趋势,并罗列了近几年来出现的"卒中地图"等中国特色的急救模式,对国内静脉溶栓治疗发展存在的局限性进行了讨论。

Intravenous alteplase at a dose of 0.9 mg/kg has become an established effective treatment for acute ischemic stroke since 1995 worldwide. However, only 4-5% of ischemic stroke patients would be treated by alteplase in China. We aim to give a brief introduction to thrombolysis treatment in China, and discuss the current problems, relative factors and development trend, and list the first-aid models with Chinese characteristics such as “stroke map” that have emerged in recent years. We also discuss the development limitations of thrombolysis treatment in China.